© Reuters. Moderna’s anti-COVID-19 vaccine could be marketed in Mexico at the end of 2023
The medical director for Latin America of Moderna (BMV:), Rolando Pajón, reported that its updated vaccine against COVID-19 could be marketed in Mexico at the end of 2023.
We would like to be in Mexico before the end of the year with our already improved vaccine so that we are not the last in the region to have access to the most updated vaccine we have against COVID-19
Pajón said in an interview for EFE.
The executive’s statements come shortly after the United States Food and Drug Administration (FDA) authorized the use of Moderna’s updated vaccine, which according to Pajón is more effective for the more contagious variants such as Omicron.
Pajón assured that clinical trials have confirmed that their vaccines against COVID-19 increased neutralizing antibodies against new circulating variants by eight to eleven times.
On the other hand, the manager regretted that regulatory approval in Mexico has not been accelerated; However, he highlighted as a “great advance” that the Mexican authorities have opened the door for private companies to market their vaccines against COVID-19.
We are ready to provide them because we think that the Mexican population deserves to have access to the best vaccine that currently exists on the market against the strains that are circulating at this time. We are willing to supply them as soon as they are approved
he added.
You may be interested: Moderna will reduce production of its vaccine against COVID-19
Vaccine maker shares fall
Despite opening up the vaccine market to private companies, U.S. drugmaker Pfizer (NYSE:) sparked a round of concerns about long-term demand for COVID-19 shots and treatments, sending shares of its partner German BioNTech (NASDAQ:) and its rival Moderna fell.
BiNTech shares fell 7.23% to 93.70 euros at the close of the markets in Europe, while at the close of Wall Street Moderna ended the day with a decrease in its shares of 6.47% to 91.94 dollars per share.
The impact on the companies’ securities comes after Pfizer reduced its forecasts for the remainder of the year in relation to the sales of its COVID antiviral treatment Paxlovid and the vaccine it developed in collaboration with BioNTech.
For its part, Moderna reported in a statement that it maintains its current revenue prospects between $6 billion and $8 billion for its COVID-19 vaccine by 2023.
For more information visit our YouTube channel
With information from Agencies
The publication Moderna’s anti-COVID-19 vaccine could be marketed in Mexico at the end of 2023 appeared first on EL CEO.
2023-10-16 22:43:44
#Modernas #antiCOVID19 #vaccine #marketed #Mexico #CEO
